HER-2

A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.

Original languageEnglish
Pages (from-to)10-18
Number of pages9
JournalJournal of Cellular Physiology
Volume205
Issue number1
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Molecular Medicine
Biomarkers
Immunotherapy
Medicine
Tumors
Breast Neoplasms
Oncogene Proteins
Neoplasms
Molecules
T-cells
Active Immunotherapy
Passive Immunization
Oncogenes
Association reactions
B-Lymphocytes
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

@article{207f0ef740164a8aa4b850501b4f232b,
title = "HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine",
abstract = "The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.",
author = "Pupa, {Serenella M.} and Elda Tagliabue and Sylvie M{\'e}nard and Andrea Anichini",
year = "2005",
month = "10",
doi = "10.1002/jcp.20387",
language = "English",
volume = "205",
pages = "10--18",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - HER-2

T2 - A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

AU - Pupa, Serenella M.

AU - Tagliabue, Elda

AU - Ménard, Sylvie

AU - Anichini, Andrea

PY - 2005/10

Y1 - 2005/10

N2 - The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.

AB - The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=24344474832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344474832&partnerID=8YFLogxK

U2 - 10.1002/jcp.20387

DO - 10.1002/jcp.20387

M3 - Article

VL - 205

SP - 10

EP - 18

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 1

ER -